The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

Katalin Piroska Kiss, Gergely Varga, G. Mikala, Katalin Balassa, Andras Bors, Petra Kovy, Nora Meggyesi, Andras Kozma, Otto Csacsovszki, Peter Remenyi, Istvan Valyi-Nagy, A. Tordai, T. Masszi, H. Andrikovics

Research output: Article

Abstract

Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the treatment applied. Among patients treated with non-proteasome inhibitor (PI)-based therapy, carriership of the minor allele was significantly associated with adverse overall survival (p=.022). In contrast, the adverse effect was overcome by the application of PI-containing treatment (p=.048). Multivariate analyses revealed the independent adverse effect of rs72773978 on survival in the non-PI-treated group (p=.045), but not in PI treatment (OS: p=.093). We confirmed the adverse prognostic effect of rs72773978 associated with non-PI-based treatment regimens. Our results point to the importance of genotypic prognostic information associated with complex clinical background MM.

Original languageEnglish
Pages (from-to)710-716
Number of pages7
JournalLeukemia and Lymphoma
Volume59
Issue number3
DOIs
Publication statusPublished - márc. 4 2018

Fingerprint

Clinical Protocols
Multiple Myeloma
Oncogenes
Proteasome Inhibitors
Genes
Receptor, Fibroblast Growth Factor, Type 1
Therapeutics
Survival
Multivariate Analysis
Alleles
Bortezomib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. / Kiss, Katalin Piroska; Varga, Gergely; Mikala, G.; Balassa, Katalin; Bors, Andras; Kovy, Petra; Meggyesi, Nora; Kozma, Andras; Csacsovszki, Otto; Remenyi, Peter; Valyi-Nagy, Istvan; Tordai, A.; Masszi, T.; Andrikovics, H.

In: Leukemia and Lymphoma, Vol. 59, No. 3, 04.03.2018, p. 710-716.

Research output: Article

Kiss, KP, Varga, G, Mikala, G, Balassa, K, Bors, A, Kovy, P, Meggyesi, N, Kozma, A, Csacsovszki, O, Remenyi, P, Valyi-Nagy, I, Tordai, A, Masszi, T & Andrikovics, H 2018, 'The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma', Leukemia and Lymphoma, vol. 59, no. 3, pp. 710-716. https://doi.org/10.1080/10428194.2017.1346250
Kiss, Katalin Piroska ; Varga, Gergely ; Mikala, G. ; Balassa, Katalin ; Bors, Andras ; Kovy, Petra ; Meggyesi, Nora ; Kozma, Andras ; Csacsovszki, Otto ; Remenyi, Peter ; Valyi-Nagy, Istvan ; Tordai, A. ; Masszi, T. ; Andrikovics, H. / The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma. In: Leukemia and Lymphoma. 2018 ; Vol. 59, No. 3. pp. 710-716.
@article{c336f509e80b41a9a194ae92e95f5432,
title = "The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma",
abstract = "Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the treatment applied. Among patients treated with non-proteasome inhibitor (PI)-based therapy, carriership of the minor allele was significantly associated with adverse overall survival (p=.022). In contrast, the adverse effect was overcome by the application of PI-containing treatment (p=.048). Multivariate analyses revealed the independent adverse effect of rs72773978 on survival in the non-PI-treated group (p=.045), but not in PI treatment (OS: p=.093). We confirmed the adverse prognostic effect of rs72773978 associated with non-PI-based treatment regimens. Our results point to the importance of genotypic prognostic information associated with complex clinical background MM.",
keywords = "bortezomib, FOPNL, Multiple myeloma, polymorphism, survival",
author = "Kiss, {Katalin Piroska} and Gergely Varga and G. Mikala and Katalin Balassa and Andras Bors and Petra Kovy and Nora Meggyesi and Andras Kozma and Otto Csacsovszki and Peter Remenyi and Istvan Valyi-Nagy and A. Tordai and T. Masszi and H. Andrikovics",
year = "2018",
month = "3",
day = "4",
doi = "10.1080/10428194.2017.1346250",
language = "English",
volume = "59",
pages = "710--716",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - The adverse effect of FOPNL genomic variant is reversed by bortezomib-based treatment protocols in multiple myeloma

AU - Kiss, Katalin Piroska

AU - Varga, Gergely

AU - Mikala, G.

AU - Balassa, Katalin

AU - Bors, Andras

AU - Kovy, Petra

AU - Meggyesi, Nora

AU - Kozma, Andras

AU - Csacsovszki, Otto

AU - Remenyi, Peter

AU - Valyi-Nagy, Istvan

AU - Tordai, A.

AU - Masszi, T.

AU - Andrikovics, H.

PY - 2018/3/4

Y1 - 2018/3/4

N2 - Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the treatment applied. Among patients treated with non-proteasome inhibitor (PI)-based therapy, carriership of the minor allele was significantly associated with adverse overall survival (p=.022). In contrast, the adverse effect was overcome by the application of PI-containing treatment (p=.048). Multivariate analyses revealed the independent adverse effect of rs72773978 on survival in the non-PI-treated group (p=.045), but not in PI treatment (OS: p=.093). We confirmed the adverse prognostic effect of rs72773978 associated with non-PI-based treatment regimens. Our results point to the importance of genotypic prognostic information associated with complex clinical background MM.

AB - Fibroblast growth factor receptor 1 oncogene partner N-terminal like gene (FOPNL) rs72773978 polymorphism was identified as an adverse prognostic factor in multiple myeloma (MM). We aimed to investigate the associations of rs72773978 with clinical characteristics and treatment outcome in 373 Hungarian MM patients. In our cohort, FOPNL polymorphism showed differential prognostic effect that depended on the treatment applied. Among patients treated with non-proteasome inhibitor (PI)-based therapy, carriership of the minor allele was significantly associated with adverse overall survival (p=.022). In contrast, the adverse effect was overcome by the application of PI-containing treatment (p=.048). Multivariate analyses revealed the independent adverse effect of rs72773978 on survival in the non-PI-treated group (p=.045), but not in PI treatment (OS: p=.093). We confirmed the adverse prognostic effect of rs72773978 associated with non-PI-based treatment regimens. Our results point to the importance of genotypic prognostic information associated with complex clinical background MM.

KW - bortezomib

KW - FOPNL

KW - Multiple myeloma

KW - polymorphism

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=85022182968&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022182968&partnerID=8YFLogxK

U2 - 10.1080/10428194.2017.1346250

DO - 10.1080/10428194.2017.1346250

M3 - Article

C2 - 28691553

AN - SCOPUS:85022182968

VL - 59

SP - 710

EP - 716

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 3

ER -